

FACT SHEET

(as of Jan. 6, 2012)

TICKER

OTCBB: UGNE

EXECUTIVE MANAGEMENT

Ashleigh Palmer
President and CEO

Greg Mayes, Esq.
VP, Corporate Development and General Counsel

Nozer Mehta, Ph.D.
VP, Biological Research and Development

Paul Shields, Ph.D.
VP, Manufacturing Operations

William Steinhauer, CPA
VP, Finance

Roxanne Tavakkol
VP, Global Regulatory Affairs and Quality Assurance

Jenene Thomas
VP, IR and Business Administration

PRIMARY INVESTOR CONTACT

Jenene Thomas
VP, IR and Business Administration
973.265.1107
jthomas@unigene.com


PRIMARY MEDIA CONTACT

Jason Rando
Tiberend Strategic Advisors, Inc.
212.827.0020
jrand@tiberend.com

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its *Peptelligence™* platform.

- ✓ Validated, proprietary oral peptide drug delivery
- ✓ State-of-the-art recombinant peptide manufacturing
- ✓ Proven peptide R&D and drug formulation expertise
- ✓ Validated manufacturing process development
- ✓ Clinical trial capabilities and regulatory expertise
- ✓ Distinctive core competence that can dominate the growing peptide sector

Targeted Growth Strategy



Commercial & Development Pipeline

Unigene's technologies have extensive clinical and partner validation:

- **Fortical®** - nasal calcitonin product; received FDA approval in 2005
- **OSTORA™** - oral calcitonin for the treatment of postmenopausal osteoporosis
- **Oral PTH** - oral parathyroid hormone for treatment of osteoporosis in postmenopausal women
- **Metabolic program**
 - **Nordic Bioscience** - oral calcitonin analogs: Type 2 diabetes, osteoarthritis, osteoporosis
 - **UGP281** - anorexigenic peptide selectively targeting the amylin receptor

	Predinical	Phase 1	Phase 2	Phase 3	Marketed	Partnership
Fortical®	—————●—————					UPSHER-SMITH
Oral Calcitonin	—————→					TARSA
Oral PTH	—————→					Actively Seeking Licensing Partner
Metabolic Peptides	—————→					High-Value Potential Partnering Opportunities
Anti-inflammatory Peptides	—————→					

RECENT NEWS
Dec. 19, 2011:

Unigene's 2011 Year in Review - Key Elements in Place to Address Debt in 2012

Dec. 5, 2011:

Unigene Regains Exclusive Worldwide Rights of Oral PTH from GSK

Nov 30, 2011:

Unigene's Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-acting Kappa Opioid Agonist

Nov. 9, 2011:

Unigene Announces Positive Top-Line Results of Phase 2 Oral PTH Study for the Treatment of Osteoporosis in Postmenopausal Women

Nov. 9, 2011:

Unigene Reports Third Quarter 2011 Financial Results

Oct. 6, 2011:

Unigene and Nordic Bioscience Combine Industry Leading Capabilities to Advance Unigene's Proprietary Peptides through Phase 2 Proof-of-Concept for the Treatment of Type 2 Diabetes, Osteoarthritis and Osteoporosis

FINANCIAL OVERVIEW
Market Cap (11/9/2011)

\$94.5MM

Cash Position (9/30/2011)

\$5.2MM

*Excludes approximately \$3.0 million in pending invoices and equity investments

Debt (9/30/2011)

\$48MM

*VPC holds \$33MM in convertible debt due 3/2013

Fully Diluted Shares Outstanding



172MM

*Including \$33MM conversion

Peptelligence™ - Peptide Development/Delivery Platform

Unigene's feasibility and formulation platform offers a distinctive set of capabilities and assets:

- ✓ Extensive IP covering delivery and manufacturing technologies
- ✓ Unsurpassed R&D expertise and know-how
- ✓ Proprietary oral peptide delivery technologies
- ✓ High-yield, scalable and reproducible *E. coli* manufacturing technologies


Industry-Leading Oral Peptide Technology


- ✓ Increased bioavailability
- ✓ More reliable therapy
- ✓ Reduced risk of toxicity
- ✓ Lower cost of goods
- ✓ Better formulation

Absolute bioavailability from 1% to greater than 20% compared to IV infusion

2012 Near-Term Catalysts

	Q1 2012	Q2 2012	Q3 2012	Q4 2012
Therapeutics Business Unit				
Oral PTH Program	Seeking Licensing Partner			
Oral Calcitonin			• Ph2 Osteopenia study results	• Ostonia™ NDA filing
UGP281 (morbid obesity)			• IND Filing	• Commence Ph1 study
50:50 Nordic JDV	• Selection of lead molecule for T2D indication		• T2D preclinical results	
Biotechnologies Business Unit				
Peptelligence™	New feasibility studies			
Cara Therapeutics	• Ph1 results		Licensing Agreement	

Multiple "game-changing" events in next 6-9 months